[Virological monitoring in subjects with HIV infection under treatment with zidovudine (AZT)]. 1990

J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
Clinica di Malattie Infettive, Università di Bari.

The authors report preliminary results of the virological evaluation (performed by serum p24 antigen detection and HIV isolation from peripheral blood lymphocytes) of Zidovudine therapy in 64 anti-HIV positive subjects. Data presented indicate that the administration of therapeutic doses of the drug can efficiently and precociously inhibit viral replication, suggesting that the clinical benefits of the therapy may be related to the anti-viral activity of the drug. However, the anti-viral efficacy of Zidovudine seems to be of limited length; in fact a reactivation of viral replication was observed in most patients during the study.

UI MeSH Term Description Entries
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014758 Viral Core Proteins Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the NUCLEOCAPSID. Core Proteins, Viral,Major Core Protein,Major Core Proteins, Viral,Adenovirus Core Protein VII,Core Protein V,Core Protein lambda 2,Influenza Virus Core Proteins,Major Core Protein lambda 1,Major Core Protein lambda-1,Major Core Protein sigma 2,Major Core Protein sigma-2,OVP 19,Oncornaviral Protein P19,P30 Core Proteins,Viral Protein P19,Virus Core Proteins,Core Protein, Major,Core Proteins, P30,Core Proteins, Virus,Protein P19, Oncornaviral,Protein P19, Viral,Protein, Major Core,Proteins, P30 Core,Proteins, Viral Core,Proteins, Virus Core
D014766 Viremia The presence of viruses in the blood. Viremias
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015683 Gene Products, gag Proteins coded by the retroviral gag gene. The products are usually synthesized as protein precursors or POLYPROTEINS, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. gag is short for group-specific antigen. Viral gag Proteins,gag Antigen,gag Gene Product,gag Gene Products,gag Polyproteins,gag Protein,gag Viral Proteins,Gene Product, gag,Retroviral Antigen gag Protein,gag Antigens,gag Gene Related Protein,gag Polyprotein,Antigen, gag,Antigens, gag,Polyprotein, gag,Polyproteins, gag,Protein, gag,Proteins, Viral gag,Proteins, gag Viral,Viral Proteins, gag,gag Proteins, Viral
D016655 HIV Core Protein p24 A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. HIV Major Core Protein p24,HIV gag Gene Product p24,HIV p24 Antigen,gag Protein p24, HIV,p24(HIV),HIV Protein p24,HTLV-III p24,p24 protein, Human Immunodeficiency Virus,HTLV III p24,p24 Antigen, HIV,p24, HIV Protein,p24, HTLV-III

Related Publications

J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
January 1990, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
September 1991, La Revue du praticien,
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
March 1989, The New England journal of medicine,
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
October 1990, Journal of paediatrics and child health,
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
January 1989, Texas Heart Institute journal,
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
October 1988, The New England journal of medicine,
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
April 1987, Lancet (London, England),
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
April 1989, The Australian nurses' journal. Royal Australian Nursing Federation,
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
November 1992, Archives of family medicine,
J R Fiore, and G Angarano, and C Fico, and S Lo Caputo, and C Fracasso, and M Barile, and G Pastore
January 2000, The Cochrane database of systematic reviews,
Copied contents to your clipboard!